药明合联 5年每股股利增长率 % : 0.00% (今日)
药明合联5年每股股利增长率 %(5-Year Dividend Growth Rate (Per Share))的相关内容及计算方法如下:
5年每股股利增长率 %是公司提高股息的平均年增长率。根据最近六年的年度数据,用最小二乘法回归计算得出。 截至今日, 药明合联 的 5年每股股利增长率 % 为 0.00%。
药明合联 5年每股股利增长率 % (HK:02268 5年每股股利增长率 %) 行业比较
在诊断和研究(三级行业)中,药明合联 5年每股股利增长率 %与其他类似公司的比较如下:
药明合联 5年每股股利增长率 % (HK:02268 5年每股股利增长率 %) 分布区间
在医疗诊断和研究(二级行业)和医疗保健(一级行业)中,药明合联 5年每股股利增长率 %的分布区间如下:
药明合联 5年每股股利增长率 % (HK:02268 5年每股股利增长率 %) 计算方法
5年每股股利增长率 %是公司提高股息的平均年增长率。根据最近六年的年度数据,用最小二乘法回归计算得出。
药明合联 5年每股股利增长率 % (HK:02268 5年每股股利增长率 %) 解释说明
1. 股息支付率 又称“股利分配率”或“股利发放率”,是向股东分派的股息占公司盈利的比率。它反映公司的股利分配政策和股利支付能力。
2. 股息率 % 是过去12个月的股息与当前股价之间的比率。在投资实践中,股息率是衡量企业是否具有投资价值的重要标尺之一。
药明合联 5年每股股利增长率 % (HK:02268 5年每股股利增长率 %) 相关词条
感谢查看价值大师中文站为您提供的药明合联5年每股股利增长率 %的详细介绍,请点击以下链接查看与药明合联5年每股股利增长率 %相关的其他词条:
药明合联 (HK:02268) 公司简介
一级行业:医疗保健
二级行业:医疗诊断和研究
公司网站:
公司地址:No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
公司简介:WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.
二级行业:医疗诊断和研究
公司网站:
公司地址:No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
公司简介:WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.